Squarepoint
NVO

Squarepoint’s Novo Nordisk NVO Stock Holding History

Squarepoint’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Sell
22,631
-109,234
-83% -$4.69M ﹤0.01% 2841
2026
Q1 		$4.85M Sell
131,865
-802,779
-86% -$38M 0.01% 1530
2025
Q4 		$47.6M Sell
934,644
-154,351
-14% -$7.89M 0.05% 417
2025
Q3 		$60.4M Buy
+1,088,995
New +$63.7M 0.06% 356
2025
Q2 		– Sell
-344,312
Closed -$23.4M – 4880
2025
Q1 		$23.9M Buy
344,312
+281,827
+451% +$23.3M 0.03% 604
2024
Q4 		$5.37M Buy
62,485
+41,936
+204% +$4.53M 0.01% 1569
2024
Q3 		$2.45M Sell
20,549
-67,676
-77% -$9.03M ﹤0.01% 1930
2024
Q2 		$12.6M Buy
88,225
+57,248
+185% +$7.59M 0.02% 818
2024
Q1 		$3.98M Buy
+30,977
New +$3.69M 0.01% 1617
2023
Q4 		– Sell
-3,908
Closed -$386K – 4336
2023
Q3 		$355K Sell
3,908
-112,282
-97% -$9.89M ﹤0.01% 3040
2023
Q2 		$9.4M Buy
116,190
+95,542
+463% +$7.8M 0.03% 710
2023
Q1 		$1.64M Sell
20,648
-7,856
-28% -$557K 0.01% 1548
2022
Q4 		$1.93M Buy
28,504
+11,268
+65% +$661K 0.01% 1388
2022
Q3 		$859K Sell
17,236
-28,926
-63% -$1.55M ﹤0.01% 1866
2022
Q2 		$2.57M Sell
46,162
-39,380
-46% -$2.19M 0.01% 1037
2022
Q1 		$4.75M Buy
85,542
+46,698
+120% +$2.4M 0.02% 746
2021
Q4 		$2.17M Buy
38,844
+29,414
+312% +$1.59M 0.01% 1208
2021
Q3 		$453K Sell
9,430
-3,338
-26% -$161K ﹤0.01% 2019
2021
Q2 		$535K Sell
12,768
-114,388
-90% -$4.43M ﹤0.01% 2079
2021
Q1 		$4.29M Buy
127,156
+64,594
+103% +$2.3M 0.03% 696
2020
Q4 		$2.19M Buy
62,562
+28,068
+81% +$970K 0.02% 893
2020
Q3 		$1.2M Sell
34,494
-74,338
-68% -$2.48M 0.02% 898
2020
Q2 		$3.56M Sell
108,832
-48,956
-31% -$1.56M 0.06% 446
2020
Q1 		$4.75M Sell
157,788
-152,266
-49% -$4.53M 0.12% 215
2019
Q4 		$8.97M Buy
310,054
+62,200
+25% +$1.72M 0.05% 337
2019
Q3 		$6.41M Buy
247,854
+42,654
+21% +$1.08M 0.06% 398
2019
Q2 		$5.24M Buy
+205,200
New +$5.07M 0.05% 427

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Squarepoint's NVO Position: Q2 2026 in Review

Squarepoint reduced its Novo Nordisk (NVO) stake by 83% in Q2 2026, selling an estimated $4.69M and leaving 22,631 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #2841.

Squarepoint first reported a position in NVO in Q2 2019 and has held it in 27 quarters since. The position peaked at $60.4M in Q3 2025. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Squarepoint held 22,631 shares of Novo Nordisk worth $1.08M as of Q2 2026.
  • Squarepoint sold 109,234 Novo Nordisk shares in Q2 2026, an estimated $4.69M.
  • Novo Nordisk made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2841 holding.
  • Squarepoint first reported a position in Novo Nordisk in Q2 2019 and has held it in 27 quarters since.
  • Squarepoint's Novo Nordisk position peaked at $60.4M in Q3 2025.
  • 1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.